钠–葡萄糖共转运蛋白2抑制剂治疗合并2型糖尿病的急性心肌梗死的研究进展
Research Progress of Sodium-Glucose Linked Transporter 2 Inhibitors in the Treatment of Acute Myocardial Infarction Complicated with Type 2 Diabetes Mellitus
DOI: 10.12677/acm.2025.152403, PDF,   
作者: 赵子轩, 范子璇：承德医学院研究生学院，河北 承德；魏庆民*：邢台市人民医院心血管内科，河北 邢台
关键词: 钠–葡萄糖共转运蛋白2抑制剂；急性心肌梗死；2型糖尿病；Sodium-Glucose Linked Transporter 2 Inhibitors； Acute Myocardial Infarction； Type 2 Diabetes Mellitus
摘要: 钠–葡萄糖共转运蛋白2 (SGLT2)抑制剂，是一种新兴口服降糖药，近年来在糖尿病治疗领域展现出了显著的临床价值。除其核心功能——有效降糖外，研究表明，SGLT2抑制剂在心血管疾病的预防与管理方面也呈现出巨大的潜力，预示着更广泛的应用前景。尽管如此，对急性心肌梗死患者应用SGLT2抑制剂的研究相对较少，本文就合并2型糖尿病的急性心肌梗死应用SGLT2抑制剂的研究进展进行综述。
Abstract: Sodium-glucose linked transporter 2 (SGLT2) inhibitors, as a new type of oral hypoglycemic drugs, have shown significant clinical value in the field of diabetes treatment in recent years. In addition to its core function of effectively lowering blood sugar, research shows that SGLT2 inhibitors also show great potential in the prevention and management of cardiovascular diseases, indicating broader application prospects. Despite this, there are relatively few studies on the use of SGLT2 inhibitors in patients with acute myocardial infarction. This article reviews the research progress on the use of SGLT2 inhibitors in patients with acute myocardial infarction combined with type 2 diabetes.
文章引用：赵子轩, 魏庆民, 范子璇. 钠–葡萄糖共转运蛋白2抑制剂治疗合并2型糖尿病的急性心肌梗死的研究进展[J]. 临床医学进展, 2025, 15(2): 750-756. https://doi.org/10.12677/acm.2025.152403

参考文献

[1] Tsao, C.W., Aday, A.W., Almarzooq, Z.I., Anderson, C.A.M., Arora, P., Avery, C.L., et al. (2023) Heart Disease and Stroke Statistics—2023 Update: A Report from the American Heart Association. Circulation, 147, e93-e621. [Google Scholar] [CrossRef] 
[2] Mensah, G.A., Fuster, V., Murray, C.J.L., Roth, G.A., Mensah, G.A., Abate, Y.H., et al. (2023) Global Burden of Cardiovascular Diseases and Risks, 1990-2022. Journal of the American College of Cardiology, 82, 2350-2473. [Google Scholar] [CrossRef] [PubMed]
[3] Von Lewinski, D., Benedikt, M., Tripolt, N., Wallner, M., Sourij, H. and Kolesnik, E. (2021) Can Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors Be Beneficial in Patients with Acute Myocardial Infarction? Kardiologia Polska, 79, 503-509. [Google Scholar] [CrossRef] [PubMed]
[4] 托波尔, 著. 霍勇, 王伟民, 高炜, 主译. 介入心脏病学[M]//赵良平, 刘海峰. 糖尿病. 第5版. 北京: 北京大学医学出版社, 2010: 25-53.
[5] Bahit, M.C., Kochar, A. and Granger, C.B. (2018) Post-Myocardial Infarction Heart Failure. JACC: Heart Failure, 6, 179-186. [Google Scholar] [CrossRef] [PubMed]
[6] Abdul-Ghani, M., Del Prato, S., Chilton, R. and DeFronzo, R.A. (2016) SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned from the EMPA-REG OUTCOME Study. Diabetes Care, 39, 717-725. [Google Scholar] [CrossRef] [PubMed]
[7] Chrysant, S.G., (2017) Promising Cardiovascular and Blood Pressure Effects of the SGLT2 Inhibitors: A New Class of Antidiabetic Drugs. Drugs of Today, 53, 191-202. [Google Scholar] [CrossRef] [PubMed]
[8] Dziuba, J., Alperin, P., Racketa, J., Iloeje, U., Goswami, D., Hardy, E., et al. (2014) Modeling Effects of SGLT‐2 Inhibitor Dapagliflozin Treatment versus Standard Diabetes Therapy on Cardiovascular and Microvascular Outcomes. Diabetes, Obesity and Metabolism, 16, 628-635. [Google Scholar] [CrossRef] [PubMed]
[9] Arnott, C., Li, Q., Kang, A., Neuen, B.L., Bompoint, S., Lam, C.S.P., et al. (2020) Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association, 9, e014908. [Google Scholar] [CrossRef] [PubMed]
[10] McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Køber, L., Kosiborod, M.N., Martinez, F.A., et al. (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381, 1995-2008. [Google Scholar] [CrossRef] [PubMed]
[11] McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic HEART failure of the European Society of Cardiology (ESC) with the Special Contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 42, 3599-3726. [Google Scholar] [CrossRef] [PubMed]
[12] Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380, 2295-2306. [Google Scholar] [CrossRef] [PubMed]
[13] Cannon, C.P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., et al. (2020) Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine, 383, 1425-1435. [Google Scholar] [CrossRef] [PubMed]
[14] Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 383, 1436-1446. [Google Scholar] [CrossRef] [PubMed]
[15] Packer, M., Anker, S.D., Butler, J., Filippatos, G., Pocock, S.J., Carson, P., et al. (2020) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 383, 1413-1424. [Google Scholar] [CrossRef] [PubMed]
[16] Anker, S.D., Butler, J., Filippatos, G., Ferreira, J.P., Bocchi, E., Böhm, M., et al. (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385, 1451-1461. [Google Scholar] [CrossRef] [PubMed]
[17] O’Meara, E., McDonald, M., Chan, M., Ducharme, A., Ezekowitz, J.A., Giannetti, N., et al. (2020) CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Canadian Journal of Cardiology, 36, 159-169. [Google Scholar] [CrossRef] [PubMed]
[18] Lipscombe, L., Butalia, S., Dasgupta, K., Eurich, D.T., MacCallum, L., Shah, B.R., et al. (2020) Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. Canadian Journal of Diabetes, 44, 575-591. [Google Scholar] [CrossRef] [PubMed]
[19] Das, S.R., Everett, B.M., Birtcher, K.K., Brown, J.M., Januzzi, J.L., Kalyani, R.R., et al. (2020) 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 76, 1117-1145. [Google Scholar] [CrossRef] [PubMed]
[20] Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., et al. (2019) 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD: The Task Force for Diabetes, Pre-Diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal, 41, 255-323. [Google Scholar] [CrossRef] [PubMed]
[21] Seferović, P.M., Fragasso, G., Petrie, M., Mullens, W., Ferrari, R., Thum, T., et al. (2020) Sodium-Glucose Co‐Transporter 2 Inhibitors in Heart Failure: Beyond Glycaemic Control. A Position Paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 22, 1495-1503. [Google Scholar] [CrossRef] [PubMed]
[22] Ren, B. and Chen, M. (2022) Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Patients with Essential Hypertension and Pre-Hypertension: A Meta-Analysis. Therapeutic Advances in Endocrinology and Metabolism, 13, 1-15. [Google Scholar] [CrossRef] [PubMed]
[23] Kawasoe, S., Maruguchi, Y., Kajiya, S., Uenomachi, H., Miyata, M., Kawasoe, M., et al. (2017) Mechanism of the Blood Pressure-Lowering Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Obese Patients with Type 2 Diabetes. BMC Pharmacology and Toxicology, 18, Article No. 23. [Google Scholar] [CrossRef] [PubMed]
[24] Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., et al. (2015) Effects of Empagliflozin on Blood Pressure and Markers of Arterial Stiffness and Vascular Resistance in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 17, 1180-1193. [Google Scholar] [CrossRef] [PubMed]
[25] Ikonomidis, I., Pavlidis, G., Thymis, J., Birba, D., Kalogeris, A., Kousathana, F., et al. (2020) Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients with Type 2 Diabetes Mellitus after 12‐Month Treatment. Journal of the American Heart Association, 9, e015716. [Google Scholar] [CrossRef] [PubMed]
[26] Ho, K.L., Zhang, L., Wagg, C., Al Batran, R., Gopal, K., Levasseur, J., et al. (2019) Increased Ketone Body Oxidation Provides Additional Energy for the Failing Heart without Improving Cardiac Efficiency. Cardiovascular Research, 115, 1606-1616. [Google Scholar] [CrossRef] [PubMed]
[27] Santos-Gallego, C.G., Requena-Ibanez, J.A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., et al. (2019) Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology, 73, 1931-1944. [Google Scholar] [CrossRef] [PubMed]
[28] Sternlicht, H. and Bakris, G.L. (2019) Blood Pressure Lowering and Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2is): More than Osmotic Diuresis. Current Hypertension Reports, 21, Article No. 12. [Google Scholar] [CrossRef] [PubMed]
[29] Packer, M. (2018) Response by Packer to Letter Regarding Article, “Activation and Inhibition of Sodium-Hydrogen Exchange Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with That of Heart Failure”. Circulation, 137, 1981-1982. [Google Scholar] [CrossRef] [PubMed]
[30] Rehman, S.U. and Rahman, F. (2020) Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus. Cureus, 12, e9655. [Google Scholar] [CrossRef] [PubMed]
[31] Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 377, 644-657. [Google Scholar] [CrossRef] [PubMed]
[32] Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 380, 347-357. [Google Scholar] [CrossRef] [PubMed]
[33] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373, 2117-2128. [Google Scholar] [CrossRef] [PubMed]
[34] Verma, S., Mazer, C.D., Yan, A.T., Mason, T., Garg, V., Teoh, H., et al. (2019) Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation, 140, 1693-1702. [Google Scholar] [CrossRef] [PubMed]
[35] Yu, Y., Zhao, X., Wang, Y., Zhou, Q., Huang, Y., Zhai, M., et al. (2021) Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Structure and Function in Type 2 Diabetes Mellitus Patients with or without Chronic Heart Failure: A Meta-Analysis. Cardiovascular Diabetology, 20, Article No. 25. [Google Scholar] [CrossRef] [PubMed]
[36] Lee, M.M.Y., Brooksbank, K.J.M., Wetherall, K., Mangion, K., Roditi, G., Campbell, R.T., et al. (2021) Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF). Circulation, 143, 516-525. [Google Scholar] [CrossRef] [PubMed]

为你推荐